Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors.
Vascular smooth muscle cells (VSMCs), unlike other muscle cells, do not terminally differentiate. In response to injury, VSMCs change phenotype, proliferate, and migrate as part of the repair process. Dysregulation of this plasticity program contributes to the pathogenesis of several vascular disorders, such as atherosclerosis, restenosis, and hypertension. The discovery of mutations in the gene encoding BMPRII, the type II subunit of the receptor for bone morphogenetic proteins (BMPs), in patients with pulmonary arterial hypertension (PAH) provided an indication that BMP signaling may affect the homeostasis of VSMCs and their phenotype modulation. Here we report that BMP signaling potently induces SMC-specific genes in pluripotent cells and prevents dedifferentiation of arterial SMCs. The BMP-induced phenotype switch requires intact RhoA/ROCK signaling but is not blocked by inhibitors of the TGFbeta and PI3K/Akt pathways. Furthermore, nuclear localization and recruitment of the myocardin-related transcription factors (MRTF-A and MRTF-B) to a smooth muscle alpha-actin promoter is observed in response to BMP treatment. Thus, BMP signaling modulates VSMC phenotype via cross-talk with the RhoA/MRTFs pathway, and may contribute to the development of the pathological characteristics observed in patients with PAH and other obliterative vascular diseases.
Lagna
Giorgio
G
Molecular Cardiology Research Institute, Tufts-New England Medical Center, Boston, MA 02111, USA. glagna@tufts-nemc.org
Ku
Manching M
MM
Nguyen
Peter H
PH
Neuman
Nicole A
NA
Davis
Brandi N
BN
Hata
Akiko
A
D000199:Actins / Q000378:metabolism; D021581:Active Transport, Cell Nucleus / Q000187:drug effects; D052006:Bone Morphogenetic Protein Receptors, Type II / Q000819:agonists / Q000378:metabolism; D019485:Bone Morphogenetic Proteins / Q000378:metabolism* / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects; D002467:Cell Nucleus / Q000378:metabolism / Q000473:pathology; D004268:DNA-Binding Proteins / Q000378:metabolism*; D053492:Elafin / Q000378:metabolism; D006801:Humans; D006976:Hypertension, Pulmonary / Q000378:metabolism* / Q000473:pathology; D009131:Muscle, Smooth, Vascular / Q000378:metabolism* / Q000473:pathology; D032389:Myocytes, Smooth Muscle / Q000378:metabolism* / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000378:metabolism*; D010641:Phenotype; D039904:Pluripotent Stem Cells / Q000378:metabolism / Q000473:pathology; D011401:Promoter Regions, Genetic; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction; D015534:Trans-Activators; D016212:Transforming Growth Factor beta / Q000378:metabolism; D020742:rhoA GTP-Binding Protein / Q000378:metabolism
D000199:Actins; D019485:Bone Morphogenetic Proteins; D004268:DNA-Binding Proteins; D053492:Elafin; C431575:MRTFA protein, human; D015514:Oncogene Proteins, Fusion; C506806:PI3 protein, human; D015534:Trans-Activators; D016212:Transforming Growth Factor beta; C066737:RHOA protein, human; D051057:Proto-Oncogene Proteins c-akt; D052006:Bone Morphogenetic Protein Receptors, Type II; D020742:rhoA GTP-Binding Protein